Medicine Experts

Frank G. Haluska

Chairman & General Manager
Respiri Limited


Dr. Haluska has served as BioCanCell’s CEO since October 2016. He most recently served as Chief Medical Officer and Senior Vice President of Clinical R&D at ARIAD Pharmaceuticals, Inc., where he held overall responsibility for clinical development strategy. At ARIAD he led the clinical development and approval of ponatinib (marketed as Iclusig) in the US, EU and other territories, as well as the development of brigatinib (marketed as Alunbrig) approved in the US by the FDA.

Research Interest

clinical trails 

Global Experts from Israel

Global Experts in Subject